Table 2.
Characteristics of patients having curative surgery for oesophagogastric cancer by time period
| Patients having curative surgery | 2012–2014 (n = 4806; 22.9%) | 2014–2016 (n = 4684; 21.9%) | 2016–2018 (n = 4246; 20.5%) | 2018–2020 (n = 3914; 19.3%) |
|---|---|---|---|---|
| Age group (years) | ||||
| ȃ<60 | 1136 (23.6) | 1137 (24.3) | 1000 (23.6) | 971 (24.8) |
| ȃ60–69 | 1690 (35.2) | 1590 (33.9) | 1433 (33.7) | 1277 (32.6) |
| ȃ70–79 | 1636 (34.0) | 1571 (33.5) | 1501 (35.4) | 1385 (35.4) |
| ȃ≥80 | 344 (7.2) | 386 (8.2) | 312 (7.3) | 281 (7.2) |
| Male sex | ||||
| 3569 (74.4) | 3505 (74.9) | 3177 (75.1) | 3001 (76.8) | |
| ȃMissing | 11 | 6 | 17 | 7 |
| Deprivation quintiles | ||||
| ȃ1 (least deprived) | 936 (19.6) | 890 (19.1) | 892 (21.1) | 800 (20.5) |
| ȃ2 | 1003 (21.0) | 1039 (22.3) | 869 (20.6) | 833 (21.4) |
| ȃ3 | 969 (20.3) | 964 (20.7) | 881 (20.9) | 805 (20.7) |
| ȃ4 | 928 (19.5) | 930 (20.0) | 818 (19.4) | 782 (20.1) |
| ȃ5 (most deprived) | 931 (19.5) | 830 (17.8) | 758 (18.0) | 677 (17.4) |
| ȃMissing | 39 | 31 | 28 | 17 |
| Comorbidities | ||||
| ȃNone | 2510 (52.2) | 2524 (53.9) | 2069 (48.7) | 1861 (47.5) |
| ȃ1 | 1262 (26.3) | 1158 (24.7) | 1280 (30.1) | 1312 (33.5) |
| ȃ2 | 691 (14.4) | 678 (14.5) | 610 (14.4) | 574 (14.7) |
| ȃ3 or more | 343 (7.1) | 324 (6.9) | 287 (6.8) | 167 (4.3) |
| Tumour group | ||||
| ȃOesophageal SCC | 414 (8.6) | 418 (8.9) | 359 (8.5) | 314 (8.0) |
| ȃOesophageal ACA upper/mid | 211 (4.4) | 239 (5.1) | 198 (4.7) | 198 (5.1) |
| ȃOesophageal ACA lower (w SI, SII) | 2456 (51.1) | 2448 (52.3) | 2229 (52.5) | 2131 (54.4) |
| ȃStomach (w SIII) | 1725 (35.9) | 1579 (33.7) | 1460 (34.4) | 1271 (32.5) |
| Clinical T category | ||||
| ȃ0/1 | 433 (9.4) | 469 (10.4) | 349 (8.6) | 293 (7.6) |
| ȃ2 | 981 (21.3) | 931 (20.6) | 861 (21.2) | 779 (20.3) |
| ȃ3 | 2561 (55.7) | 2519 (55.6) | 2256 (55.6) | 2134 (55.6) |
| ȃ4 | 361 (7.9) | 400 (8.8) | 371 (9.1) | 406 (10.6) |
| ȃX | 259 (5.6) | 209 (4.6) | 223 (5.5) | 223 (5.8) |
| ȃMissing | 211 | 156 | 186 | 79 |
| Clinical N category | ||||
| ȃ0 | 1967 (42.8) | 1953 (43.1) | 1864 (45.9) | 1727 (45.0) |
| ȃ1 | 1770 (38.5) | 1733 (38.3) | 1412 (34.8) | 1365 (35.6) |
| ȃ2 | 608 (13.2) | 605 (13.4) | 614 (15.1) | 571 (14.9) |
| ȃ3 | 140 (3.0) | 148 (3.3) | 110 (2.7) | 100 (2.6) |
| ȃX | 110 (2.4) | 89 (2.0) | 60 (1.5) | 72 (1.9) |
| ȃMissing | 211 | 156 | 186 | 79 |
| Performance status | ||||
| ȃ0 | 2532 (52.7) | 2678 (57.2) | 2479 (58.4) | 2509 (64.1) |
| ȃ1 | 1748 (36.4) | 1677 (35.8) | 1466 (34.5) | 1230 (31.4) |
| ȃ≥2 | 526 (10.9) | 329 (7.0) | 301 (7.1) | 175 (4.5) |
Values are n (%) unless otherwise stated. SCC, squamous cell carcinoma; ACA, adenocarcinoma; w SI–III, with Siewert type I–III.